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Abstract
Background: The diagnostic and prognostic assessments of infective endocarditis (IE) are challenging. To investigate the
host response during IE and to identify potential biomarkers, we determined the circulating gene expression profile using
whole genome microarray analysis.
Methods and Results: A transcriptomic case-control study was performed on blood samples from patients with native valve
IE (n=39), excluded IE after an initial suspicion (n=10) at patient’s admission, and age-matched healthy controls (n=10).
Whole genome microarray analysis showed that patients with IE exhibited a specific transcriptional program with a
predominance of gene categories associated with cell activation as well as innate immune and inflammatory responses.
Quantitative real-time RT-PCR performed on a selection of highly modulated genes showed that the expression of the gene
encoding S100 calcium binding protein A11 (S100A11) was significantly increased in patients with IE in comparison with
controls (P,0.001) and patients with excluded IE (P,0.05). Interestingly, the upregulated expression of the S100A11 gene
was more pronounced in staphylococcal IE than in streptococcal IE (P,0.01). These results were confirmed by serum
concentrations of the S100A11 protein. Finally, we showed that in patients with IE, the upregulation of the aquaporin-9
gene (AQP9) was significantly associated with the occurrence of acute heart failure (P=0.02).
Conclusions: Using transcriptional signatures of blood samples, we identified S100A11 as a potential diagnostic marker of IE,
and AQP9 as a potential prognostic factor.
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Introduction
Infective endocarditis (IE) is a severe disease with an incidence
ranging from 30 to 100 episodes per million person-years [1,2].
Mortality is high, and more than one-third of the patients die
within the first year of their diagnosis [3,4,5,6]. Despite the
development of microbiological and imaging techniques, the
diagnosis of IE remains challenging. Indeed, etiologic diagnoses
may not be obtained in 2.5% to 31% of cases [1,7], and
echocardiography is negative for approximately 10% of cases [1].
Thus, morbidity and mortality remain high, and strategies fail to
detect and predict a substantial number of events, such as heart
failure and embolic events. One of the reasons for these issues is
the complex pathogenesis of the disease that involves many host-
pathogen interactions. Indeed, previous endocardial lesions can
lead to the exposure of the underlying extracellular matrix
proteins, local inflammation with interleukin-1 release, and then
thrombus formation, which is termed ‘‘non-bacterial vegetation’’.
In the case of bacteremia, valves with pre-existing sterile
vegetations or tissues with minimal lesions can be colonized
because of crucial interactions between the bacteria, platelets and
endothelial cells via several bacterial surface proteins or plasma-
bridging molecules. This process leads to the recruitment of
circulating cells, including neutrophils and monocytes, the release
of cytokines and procoagulant factors that contribute to the
enlargement of vegetations and the protection of bacterial
pathogens from host defenses [2].
This complex situation highlights the need for methods that
improve the management of IE. Specifically, the identification of
new biomarkers for diagnosis and risk stratification will be useful,
as well as biological indicators for a rapid surgical management.
Molecular signatures of IE represent promising means for
addressing these challenges. In particular, microarray-based
transcriptomes can identify specific signatures of the disease that
might ultimately be translated into clinically useful molecular
biomarkers [3]. Recently, we identified a transcriptional signature
of IE from valvular tissue [4], but this approach cannot be used by
physicians in their daily practice. Peripheral blood is an alternative
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because it interacts with every tissue in the body and plays a
crucial role in many IE pathophysiological processes, such as
immunity, inflammation and coagulation.
To investigate the host response during IE and identify potential
biomarkers, we determined the circulating gene expression profile
through a unique whole genome microarray analysis. We show
that patients with IE exhibited a specific transcriptional program
with a predominance of gene categories associated with cell
activation as well as innate immune and inflammatory responses.
We demonstrate that the gene encoding the S100 calcium binding
protein A11 (S100A11) and the serum concentration of S100A11
protein are both significantly increased in IE patients, especially in
the case of staphylococcal etiology. Moreover, in IE patients, the
upregulation of the aquaporin-9 gene (AQP9) is associated with the
occurrence of acute heart failure.
Methods
Study Population
All participants in the study were prospectively enrolled from
January 2009 to December 2010 at the Cardiology Department of
La Timone Hospital (Marseille, France), which is an adult tertiary
care teaching hospital. The patients were eligible for the study if
they had a clinical suspicion of native valve IE. The exclusion
criteria were age ,18 years, pregnancy, history of previous IE,
intracardiac material (prosthetic valve, pacemaker or implantable
cardioverter defibrillator), failure in the RNA extraction proce-
dure, and an antibiotic treatment for more than one week. Among
the 71 patients eligible for the study, 22 were excluded because of
the presence of at least one exclusion criterion. Their baseline
characteristics are summarized in Table 1.
The transcriptomic case-control study was performed in:
i. 39 consecutive patients with native valve IE (IE group)
diagnosed by a multidisciplinary team who applied the
modified Duke criteria [5] (two major criteria in 37 patients
and 1 major with 3 minor criteria in 2 patients),
ii. 10 patients with a previous valvular heart disease (VHD)
admitted for a suspicion of IE because of persistent fever or
new abnormalities detected by echocardiography, but with a
final excluded IE diagnosis (excluded IE group). Of these, the
final diagnosis was an acute degenerative mitral chordae
rupture (n=4), a respiratory tract infection (n=2), an urinary
tract infection (n=1), and no diagnosis after a 3-month
follow-up (n=3). Among these 3 patients, fever disappeared
spontaneously without antibiotics.
iii. 10 age-matched healthy volunteers (control group).
Initially, 10 IE patients and 5 controls were arbitrarily selected,
and their samples were analyzed with microarrays; however,
samples from all of the patients were eventually analyzed by
quantitative real-time reverse transcriptase-polymerase chain
reaction (qRT-PCR).
For each case, the following data were collected: age, sex,
comorbidity [6], signs and symptoms, duration of symptoms,
biological results, history of antimicrobial therapy for the current
illness that prompted the patient to seek medical attention,
antecedent disease, predisposing factors for IE including systemic
disease, intravenous drug use, treatment received during the
course of hospitalization and complications (acute heart failure,
embolic event, and cardiac abscess). Echocardiography was
performed by a systematic transthoracic and trans-esophageal
approach [5]. For the microbiological diagnosis, a diagnostic kit,
including blood cultures and serologies, was used as previously
described [7]. When cardiac surgery was required, valvular
surgical samples were analyzed using cultures and PCR amplifi-
cation.
The study was performed according to the principles of the
Declaration of Helsinki. Informed and written consent was
obtained from each subject, and the Ethics Committee of the
Universite ´d el aM e ´diterrane ´e approved the study.
RNA Preparation and Microarrays
At the admission of patients, peripheral blood was drawn into
PAXgene tubes (Qiagen). The RNA was extracted according to
the manufacturer’s recommendations, which included a DNase
step. The quality and quantity of isolated RNAs were assessed
using the Nanodrop (Thermo Scientific) and 2100 Bioanalyzer
(Agilent Technologies), and the RNAs were eluted in 80 mLo f
water and stored at 220uC. Subsequently, the RNAs were
analyzed using microarray chips (Agilent Technologies), including
45,000 probes (4644 K Whole Human Genome, Agilent
Technologies) and one-color microarray-based gene expression
analysis, as recently described [8]. Briefly, 400 ng of RNA was
labeled with cyanine-3 CTP using a commercial kit (Low RNA
Table 1. Characteristics of the patients according to the final
diagnosis.
IE group
(N=39)
Excluded
IE group
(N=10) P Value
Age, mean 6SD, years 58618 63615 0.42
Sex ratio (M/F) 30/9 7/3 0.65
Intravenous drug user 5 (13%) 0 (0%) 0.57
Cancer 3 (8%) 1 (10%) 1.0
Diabetes 5 (13%) 1 (10%) 1.0
Comorbidity index .2 15 (38%) 3 (30%) 0.72
Fever, temperature .38uC 38 (97%) 7 (70%) 0.02
Vascular phenomena* 14 (36%) 1 (10%) 0.15
Immunologic phenomena{ 0 (0%) 0 (0%) NA
Heart failure 16 (41%) 5 (50%) 0.72
Serum creatinine .20 mg/L 3 (8%) 1 (10%) 1.0
Valve localization of abnormality 1.0
Aortic 17 (44%) 4 (40%)
Mitral 23 (59%) 6 (60%)
Right valves 3 (8%) 0 (0%)
Severe valvular regurgitation 32 (82%) 7 (70%) 0.41
Vegetation 32 (82%) 0 (0%) ,0.001
Abscess 10 (26%) 0 (0%) ,0.001
Blood cultures ,0.001
Streptococci{ 27 (69%) 0 (0%)
Staphylococci1 12 (31%) 1 (10%)
Negative 0 (0%) 9 (90%)
NA=not applicable.
*Including arterial emboli, septic pulmonary infarcts, mycotic aneurysms,
intracranial hemorrhages, conjunctival hemorrhages, and Janeway’s lesions.
{Including glomerulonephritis, Osler’s nodes, Roth’s spots, and rheumatoid
factor.
{Including three enterococci.
1Including nine Staphylococcus aureus.
doi:10.1371/journal.pone.0031490.t001
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were deposited on a slide, and hybridization was performed at 65uC
using the In situ Hybridization Plus kit (Agilent Technologies) for
17 hours. The arrays were scanned with a pixel size of five microns
using the DNA Microarray Scanner G2505B (Agilent Technologies).
The image analysis and correction of intra-array signals were
performed with the Feature Extraction Software A.9.1.3 (Agilent
Technologies). Microarray data analysis was performed using the R
and the Bioconductor software suite. Raw data were filtered and
normalized using the Agi4x44PreProcess library. Unsupervised and
supervised analysis were done using hierarchical clustering, principal
component analysis (made4 library) [9], and Significance Analysis of
Microarray (SAM) algorithm (siggenes library). Genes were considered
to be differentially expressed if False Discovery Rate (FDR,
Benjamini-Hochberg [10]) was below 1% and absolute fold change
was above 1.5. Functional enrichment analysis was performed on
selected genes with DAVID Tools [11], using the following
ontologies: Gene Ontology (GO) [12], INTERPRO [13] and KEGG
pathways [14]. The figures were designed using Cytoscape [15] and
Inkscape softwares. The data were generated according to the
Minimum Information About a Microarray Experiment guidelines
and were deposited in the National Center for Biotechnology
Information’s Gene Expression Omnibus [16]. The data are
accessible using the following accession number: GSE29161.
qRT-PCR Analyses
Reverse transcription of 150 ng of total RNA per reaction was
performed with the MMLV-RT kit (Invitrogen), as previously
described [8]. Quantitative real-time PCR was performed using
gene-specific primers designed using Primer3 [17]. The list of
primers with their sequences is provided in the Table S1. The
transcriptional profiles of the selected genes were screened in
homemade 384-well plates using the 7900HT Fast Real Time
PCR System, and the qRT-PCR data were extracted using the
SDS 2.2 software (Applied Biosystems). The results were
normalized using the housekeeping gene b-actin and are expressed
as FC=2
–DDCt, where DDCt=(CtTarget2CtActin)assay2(CtTar-
get2CtActin)control, as previously described [8].
S100A11 Assay
The serum concentrations of S100A11 protein were assessed by
enzyme-linked immuno-sorbent assay kit (USCN, Life Science
Inc.) according to the manufacturer’s protocol. The sensitivity of
the test is 0.37 ng/mL.
Statistical Analysis
The categorical data were reported as frequencies and
percentages and were compared using the Fischer exact two-
tailed test. The continuous data are expressed as the mean 6 SEM
or the median and interquartile range. Comparisons between two
groups were performed using the Mann-Whitney U test, and
comparisons between the three groups of individuals were
performed using the Kruskal-Wallis test with post-hoc Dunn’s
multiple comparison test. This statistical analysis was conducted
using SPSS for Windows, version 16.0 (SPSS Inc., Chicago,
Illinois). Values of P,0.05 were considered statistically significant.
Results
Microarray Analysis of Patients with IE
A whole-genome microarray approach was used to define the
peripheral transcriptional signature of IE. For that purpose, we
Figure 1. Gene expression signature between endocarditis and control patients. Differential gene expression between infective
endocarditis (IE) and control patients was analyzed by Principal Component Analysis (A) and Hierarchical clustering (B). In panel A, IE patients (red) are
clearly separated from control patients (blue) on the first component (x-axis) of the PCA. In panel B, selected genes with FDR,1% and absolute fold
change above 1.5 were represented as a heatmap, with genes in rows and samples in columns. Gene expression level was color-coded from blue to
red.
doi:10.1371/journal.pone.0031490.g001
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components for the analysis of the overall gene expression showed
that the IE patients and controls were organized in two different
groups (Figure 1, Panel A). Supervised analysis using the SAM
algorithm identified 1,782 probes differentially expressed with an
absolute fold change above 1.5, and a FDR,1% (Figure 1, Panel
B). Modulated genes in the IE patients and controls were
distributed in two different clusters. Finally, we found that 1,274
probes (912 genes) were upregulated and 508 probes (339 genes)
were downregulated in IE patients compared with controls. Taken
together, these different analyses of the gene expression demon-
strated that the patients with IE exhibited a specific transcriptional
program.
Functional Analysis of Modulated Genes in Patients with
IE
The genes that were differentially expressed in IE patients were
classified into different categories based on GO, SP_PIR key-
words, Interpro and KEGG ontologies (Table 2). In the
upregulated genes, there was an enrichment of the biological
processes related to cell activation, post-translational modification
of proteins, intra-cellular transport and localization, phagocytosis
and immune response. Post-translational modification of proteins
was supported by the following terms: ‘‘acetylation’’, ‘‘ubiquitin
conjugation pathway’’ and ‘‘modification-dependant protein
catabolic process’’. Intra-cellular transport and localization, as
well as phagocytosis were supported by the following terms:
‘‘establishment of protein localization’’, ‘‘protein transport’’,
‘‘vesicle mediated transport’’, ‘‘golgi apparatus’’, ‘‘lysosome’’,
‘‘endosome’’ and FC-c receptor mediated phagocytosis’’. These
latter terms, together with the terms ‘‘host-virus interaction’’,
‘‘regulation of I-kappaB kinase/NF-kappaB cascade’’, ‘‘Zing
finger, RING-type’’ and ‘‘defense response’’ support the involve-
ment of the up-regulated genes in the immune response. In the
downregulated genes, the GO terms corresponding to cation
binding, extracellular matrix and regulation of vesicle-mediated
transport were enriched. Two KEGG pathway linked to the
immune response were enriched in the upregulated signature:
‘‘lysosome’’ and ‘‘FC-c receptor mediated phagocytosis’’.
Validation of Modulated Genes in Patients with IE
Because of the large number of modulated genes and the density
of transcriptomic networks, the following procedure was used to
validate the microarray data. Seven upregulated genes were
selected from a list of the 300 most modulated genes according to
their putative role in IE pathophysiology. Their expression was
determined by qRT-PCR in an enlarged cohort of IE patients
(n=39) and controls (n=10). The genes encoding aquaporin-9
Table 2. Ontology enrichement analysis.
Ontology ID Count P-value Term
Up-regulated
SP_PIR - 287 1.1610
214 Acetylation
SP_PIR - 75 2.7610
210 Protein transport
SP_PIR - 75 2.4610
29 Ubiquitin conjugaison pathway
GO_BP 0045184 101 6.1610
28 Establishment of protein localization
GO_BP 0019941 81 7.7610
28 Modification-dependent protein catabolic process
GO_MF 0032555 199 8.9610
28 Purine ribonucleotide binding
GO_BP 0016192 81 9.0610
28 Vesicle mediated transport
GO_BP 0044257 83 1.5610
28 Cellular protein catabolic process
GO_CC 0005794 102 6.5610
27 Golgi apparatus
GO_CC 0005764 35 6.4610
26 Lysosome
SP_PIR - 41 2.6610
25 Host-virus interaction
GO_CC 0005768 44 3.1610
25 Endosome
KEGG hsa04142 24 7.4610
25 Lysosome
GO_BP 0007242 132 8.5610
25 Intra-cellular signalling cascade
KEGG hsa04666 20 2.5610
24 FC-g receptor mediated phagocytosis
GO_BP 0043122 20 4.2610
24 Regulation of I-kappaB kinase/NF-kappaB cascade
Interpro 0017907 37 8.4610
24 Zinc-finger, RING-type
GO_BP 0006952 68 1.8610
23 Defense response
Down-regulated
GO_MF 0046872 133 7.1610
24 Metal ion binding
GO_MF 0043169 134 8.2610
24 Cation binding
Interpro 019787 9 1.1610
23 Zinc-finger, PHD finger
GO_CC 0031012 19 1.3610
23 Extracellular matrix
GO_BP 0042127 82 1.9610
23 Regulation of cell proliferation
GO_BP 0060627 9 2.3610
23 Regulation of vesicle mediated transport
Interpro 013098 11 2.7610
23 Immunoglobulin I-set
doi:10.1371/journal.pone.0031490.t002
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(PLAUR), solute carrier family 16, member 3 (SLC16A3),
transforming growth factor beta 1 (TGFb1), interferon gamma-
inducible protein 16 (IFI16), apolipoprotein B mRNA editing
enzyme, and catalytic polypeptide-like 3B (APOBEC3B) were
significantly upregulated in IE patients (P,0.001 for all, Figure 2).
Because these results may be due to the underlying valvular
abnormality or the global inflammatory response, they were
compared with those obtained in the group of patients with
excluded IE after an initial suspicion (n=10). The S100A11 gene
was significantly upregulated in the IE patients as compared with
the patients with excluded IE (P,0.05, Figure 2). The upregulated
expression of the S100A11 gene had functional consequences.
Indeed, the serum concentration of S100A11 protein was higher in
patients with IE than in patients with excluded IE (5.061.0 versus
2.160.5 ng/mL, P,0.05).
Finally, we tested whether the bacterial etiology of IE plays a
role in the modulated expression of the S100A11 gene. In our
series, 23 patients were infected with staphylococci (Staphylococcus
aureus in nine patients) and 16 patients with streptococci. The
expression of the S100A11 gene was significantly higher in
staphylococcal IE than in streptococcal IE and patients with
excluded IE (P,0.01 and P,0.001, respectively) (Figure 3, Panel
A). Similarly, the serum concentration of S100A11 protein was
slightly increased in staphylococcal IE when compared with
streptococcal IE and was significantly (P,0.05) increased when
compared with patients with excluded IE (Figure 3, Panel B).
Taken together, these results suggested that the determination of
S100A11 at both the transcriptional and the protein levels was
potentially predictive of IE. The S100A11 determination also
discriminated between staphylococcal and streptococcal IE.
IE Transcriptional Signature and Major IE-Related
Complications
Finally, we analyzed the modulation of the seven genes by qRT-
PCR at admission according to IE-related complications,
including acute heart failure (n=17), embolic events (n=14),
and cardiac abscess (n=10). The expression of the AQP9 gene was
increased only in patients who experienced acute heart failure
(P,0.05). The expression of the S100A11, PLAUR, SLC16A3,
TGFb1, IFI16, and APOBEC3B genes was not related to acute
heart failure, embolic events, or abscess (Figure 4). Taken together,
these results suggested that the AQP9 gene might be a marker of
prognosis in IE.
Discussion
The aim of the present study was to characterize the peripheral
transcriptional profile of patients with IE and to identify potential
biomarkers. The clinical history of IE is dependent on the
causative microorganism, the presence or absence of pre-existing
cardiac disease, and the mode of presentation. The modified Duke
criteria for IE diagnosis have been validated [5]; but they have
clear limitations, especially when blood cultures and/or echocar-
diography are negative. Other parameters have been proposed to
increase the yield of the diagnostic process, but none have been
definitely implemented into the diagnostic criteria. A small study
suggested that serum procalcitonin may be a valuable diagnostic
marker in patients with suspected IE [18]. New imaging
techniques, such as computed tomography (CT) [19], positron
emission tomography/CT scan [20], three-dimensional echocar-
diography [21], or systematic cerebral MRI [22], are emerging to
improve IE diagnosis; their final place has yet to be defined. The
transcriptional analysis of a disease is a promising method to
identify novel candidate biomarkers that might ultimately be
translated into clinical practice [3]. In the present study, we found
that blood transcriptomics may be used to characterize IE. We
Figure 2. Analysis of genes modulation using qRT-PCR. Blood samples from 39 patients with IE, 10 patients with excluded IE after an initial
suspicion, and 10 controls were analyzed by qRT-PCR for the expression of seven genes that were found to be upregulated by microarray. The results
were normalized with the b-actin gene. *P,0.001 for the comparison between IE patients and controls. {P,0.05 for the comparison between IE
patients and patients with excluded IE.
doi:10.1371/journal.pone.0031490.g002
Figure 3. Expression of S100A11 gene and S100A11 protein. A,
The S100A11 gene was significantly overexpressed in IE patients as
compared with excluded IE patients (P,0.05). *P,0.001 for the
comparison between staphylococcal IE and excluded IE. {P,0.01 for
the comparison between staphylococcal IE and streptococcal IE. B, The
S100A11 serum level was higher in staphylococcal IE (6.962.0 ng/mL)
than in excluded IE (2.160.5 mg/mL) and staphylococcal IE (4.261.2 ng/
mL). {P,0.05 for the comparison between staphylococcal IE and
excluded IE. 1P=0.17 for the comparison between staphylococcal IE
and streptococcal IE.
doi:10.1371/journal.pone.0031490.g003
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[4]; to our knowledge, this is the first time that the host response in
IE was studied at the blood level, which is more accessible and
relevant than valvular tissue in the clinical practice.
The present analysis of the peripheral signature of IE allowed
the identification of potential candidates for the diagnostic and
prognostic assessment of IE. We showed that the expression of the
S100A11 gene was increased in patients with a final diagnosis of IE
as compared with patients with an excluded IE diagnosis after an
initial suspicion. The increased expression of the S100A11 gene
was essentially related to Staphylococcus infection. These transcrip-
tional results were consistent with higher serum concentrations of
the S100A11 protein in IE patients. S100A11 is a member of the
family of S100 proteins that are localized in the cytoplasm and/or
nucleus of a wide range of cells. S100A11 proteins are involved in
endocytosis and exocytosis [23], regulation of enzyme activity, cell
growth regulation, apoptosis and inflammation [24]. Note that
endocytosis and inflammation were two hallmarks of the
peripheral signature of IE determined in this study. Regarding
the role of S100A11 in the pathophysiology of IE, our analysis
extracted from the litterature a pathway that involves receptor for
advanced glycation end-products (RAGE) and S100A11, which is
one of its ligand. RAGE ligation causes cellular activation via
signalling cascades including nuclear factor NF-kB, MAP kinases
leading to induction of inflammatory cytokines, proteases ans
oxydative stress [25]. NF-kB and the presence of RAGE ligand
also up-regulates RAGE expression, ensuiring maintenance and
amplification of the initial signal (Figure 5). RAGE and their
ligands are strongly involved in the pathogenesis of systemic
inflammation and represent a potential therapeutic target in sepsis
and several acute infectious diseases [26]. Although S100A protein
family can be associated with several human diseases, such as
neurological diseases, cardiomyopathy, cancers, and inflammatory
diseases, only few data exist on the specific implication of the
S100A11 in pathology. In our microarray analysis, we compared
IE patients with healthy subjects in order to bring out great
significant differences with a small sample size. Thereafter, we
analyzed S100A11 gene expression in a population of patients with
Figure 4. Gene expression according to the major IE-related complications. A, The expression of the AQP9 gene was significantly increased
only in patients who experienced acute heart failure. B and C, The expression of the S100A11, PLAUR, SLC16A3, TGFb1, IFI16, and APOBEC3B genes
was not related to acute heart failure, embolic events, or abscess. *P,0.05.
doi:10.1371/journal.pone.0031490.g004
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Obviously, our study did not demonstrate that a single dosage of
S100A11 is appropriate for the definite diagnosis of IE whatever
the situation. Indeed, it does not make sense to use S100A11
without a specific clinical context. Our study showed that, in the
case of a clinical suspicion of IE (i.e. a specific population of
patients), S100A11 might be a marker of the IE diagnosis in
association with other parameters. Moreover, the primers used for
RT-PCR were specific and did not amplify the other S100A
proteins. Finally, our results were significant both by RT-PCR
(S100A11 gene expression) and enzyme-linked immuno-sorbent
assay (S100A11 protein in the serum). Thus, our results are
probably not due to chance. Since our work was an exploratory
study (first step to determine new candidate biomarkers for IE), we
cannot definitely consider S100A11 as a biomarker for the
diagnosis of IE, but this investigation open new perspectives for
future studies that will test its sensibility and specificity in larger
populations of patients with a clinical suspicion of IE.
In addition, the expression of the AQP9 gene was clearly
increased in IE patients who experienced acute heart failure,
suggesting that its determination may be useful to the prognosis of
IE. The detection of predictors of acute heart failure is of crucial
importance because it can indicate the need for valvular surgery at
an early stage of the disease [27]. Despite the identification by
echocardiography and biological factors that are associated with
acute heart failure [2], this complication remains the first cause of
death during IE [5]. This fact highlights the need for additional
markers. The AQPs are cell membrane-embedded proteins that
facilitate water movements by increasing membrane water
permeability and water flux in response to osmotic gradients
[28]. The AQPs are involved in multiple different pathological
processes, including abnormalities of renal function [28], myocar-
dial [29], and brain [30] edema. Interestingly, we previously
reported that the AQP9 gene is overexpressed in the valvular tissue
of IE patients and that the AQP9 protein is expressed in
endothelial cells lining the lumen of neo-vessels [4]. The
association between the modulation of the expression of the
AQP9 gene and acute heart failure may be due to the upregulation
of the AQP9 gene in patients with the most severe valvular
damages. Patients with fluid retention may also differently express
the AQP9 gene in organs, such as the lungs and kidneys. These
hypotheses offer new perspectives in the prognostic assessment of
patients with IE and could have therapeutic implications because
patients at high risk for hemodynamic instability are candidates for
Figure 5. S100A11 relationship with RAGE pathway. RAGE pathway and its relationship with S100A11 were extracted from the literature and
shematically represented on top of a virtual cells. Activation of inflammatory molecules induce the release of S100A11. S100A11 can homodimerize
by interacting with its ‘‘EF-hand’’ domains. Transglutaminase TGM2 creates covalent bounds and a stable S100A11 homodimer. This S100A11 dimer
interact with RAGE receptor, which in turn activates the MAP kinase pathway, and transduce membrane signals to the nucleus. The key transcription
factors NF-kB, SP1, FOS and JUN, and ELK1 then up-regulate the transcription of their target genes.
doi:10.1371/journal.pone.0031490.g005
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small sample size restricts the statistical power of our study, for
exemple, confounding factors other than age have not been
addressed in the analysis. Thus, it may be useful to extend our
results to a larger cohort of patients to confirm the clinical
relevance of the use of both biomarkers for the diagnosis and
prognosis of IE.
In summary, we are the first to report the circulating gene
expression profile of IE patients. This peripheral signature enabled
us to address, at least in part, the complex pathogenesis of IE. Our
analyses revealed an enrichment of processes related to cell
activation and the inflammatory and immune responses. The
identification of novel candidates, such as S100A11 and AQP9, for
diagnostic and prognostic assessment has likely provided new
perspectives for future clinical studies.
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